Personalized Medicine Meets Payment Policy: MEDCAC Has “Low Confidence” In Most Cancer Tests
This article was originally published in RPM Report
Executive Summary
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?